CD279 (PD1) Antibody, anti-mouse, FITC 130-102-249 from Miltenyi Biotec | Biocompare.com

Be the first to write a review!

Citations:

Supplier Page from
Miltenyi Biotec for
CD279 (PD1) Antibody, anti-mouse, FITC

Miltenyi Biotec's CD279 (PD1) Antibody, anti-mouse, FITC is a Rat monoclonal antibody. The CD279 (PD1) Antibody, anti-mouse, FITC was generated using PDCD1 as the antigen. It reacts with Mouse. This antibody has been shown to work in applications such as: Staining, Fluorescence, Microscopy, Flow Cytometry, Immunofluorescence, and Immunohistochemistry.

Product Specs
ItemCD279 (PD1) Antibody, anti-mouse, FITC
CompanyMiltenyi Biotec
Price Pricing Info Supplier Page View Company Product Page
Catalog Number130-102-249
Quantity30 µg in 1 mL
ApplicationsFlow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry
Conjugate/TagFITC
FormatReagents are supplied in buffer containing stabilizer and 0.05% sodium azide
Reactivitymouse
TargetCD279 (PD1)
IsotypeIgG2b
CloneHA2-7B1
Hostrat
Antibody TypePrimary antibodies
NCBI Full Gene Nameprogrammed cell death 1
NCBI Gene AliasesLy101, PD-, PD-1, Pdc, Pdc1
Clonalitymonoclonal
Regulatory StatusFor research use only
Concentration1:10
Research AreaFor research use only

Add to Compare List

Miltenyi Biotec

Local Office

Miltenyi Biotec

Miltenyi Biotec Inc.

2303 Lindbergh Street

Auburn, CA 95602

United States

Phone: Phone: +1 530 888 8871
Toll Free: 800 FOR MACS
Fax: +1 530 888 8925

Email: macs@miltenyibiotec.com

Company Profile

Website: www.miltenyibiotec.com

International Office

Miltenyi Biotec

Miltenyi Biotec B.V. & Co. KG

Friedrich-Ebert-Straße 68

51429 Bergisch Gladbach

Germany

Phone: +49 2204 8306-0
Fax: +49 2204 8306-235

Email: macs@miltenyibiotec.de

Company Profile

Website: www.miltenyibiotec.com

(1) Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergyBloodJuly 1, 2007Tsushima F, Yao S, Shin T, Flies A, Flies S, Xu H, Tamada K, Pardoll DM, Chen L.

(2) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunityCancer researchFebruary 1, 2005Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, et al.

(3) Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitisThe Journal of experimental medicineJuly 7, 2003Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, Tushima F, Azuma M, Yagita H, Sayegh MH, Khoury SJ.

(4) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences of the United States of AmericaSeptember 17, 2002Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N.

Be the First to Write a Review!